An unresolved concern in oncology is the need to develop new diagnostic and therapeutic options for Primary Hepatic Angiosarcoma (PHA). In furthering the development and therapy of PHA, Protheragen provides a full range of services directed toward the enhancement of primary hepatic angiosarcoma (PHA) diagnostics and therapeutics development.
Overview of Primary Hepatic Angiosarcoma (PHA)
Primary Hepatic Angiosarcoma (PHA) is an exceptionally uncommon and highly aggressive neoplasm that arises from the endothelium of the liver's blood vessels. It constitutes roughly 2% of all the hepatic malignancies and remains among the rarest and hardest to diagnose cancers. It is usually diagnosed in individuals above 50 years of age and has a greater prevalence in males than females. This tumor is usually noted to have a very rapid progression, a high degree of metastasis, and a very poor prognosis. Most patients diagnosed with this disease already have advanced-stage conditions such as liver failure, tumor necrosis, or metastatic spread to the lungs, bones, and peritoneum.
Fig.1 A case study of histopathological analysis of primary hepatic angiosarcoma (PHA). (Jiang L.,
et al., 2021)
Pathogenesis of Primary Hepatic Angiosarcoma (PHA)
Both genetics and environmental factors are part of PHA's multi-faceted etiology. The environmental aspects are exposures to potential carcinogens like vinyl chloride, arsenic, and thorium dioxide (thorotrast). These substances are known to induce genetic mutations and promote tumorigenesis. In PHA patients, there are also some changes in the genetic landscape, with known mutations in K-ras and p53 which lead to abnormal cell growth and tumorigenesis. Tumors of the angiosarcoma type can also be associated with chronic lymphedema and radiation exposure.
Diagnostics Development for Primary Hepatic Angiosarcoma (PHA)
- Histopathological Examination
A definitive diagnosis of PHA is typically made through histopathological examination of biopsy specimens. Immunohistochemical staining for markers such as CD31, CD34, and FLI-1 is essential for confirming the diagnosis. These markers highlight the presence of abnormal endothelial cells and vascular structures, characteristic of angiosarcomas.
- Serological Tests
Serological tests, including tumor markers such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9), are often within the normal range in PHA patients. However, these tests can help rule out other liver malignancies and provide additional diagnostic information.
Therapeutics Development for Primary Hepatic Angiosarcoma (PHA)
- Chemotherapy: Systemic chemotherapy is often used for patients with unresectable PHA. Common regimens include doxorubicin, paclitaxel, and gemcitabine. While chemotherapy can provide palliative benefits, its efficacy in achieving long-term remission is limited. Ongoing research aims to identify more effective chemotherapy agents and combinations.
- Targeted Therapies: Targeted therapies, such as bevacizumab and sorafenib, have shown promise in preclinical studies. These agents target specific molecular pathways involved in tumor growth and angiogenesis, potentially offering more effective therapy options for PHA cases.
- Immunotherapy: Immunotherapy, including checkpoint inhibitors such as pembrolizumab and ipilimumab, is an emerging therapy modality for PHA. Early studies have demonstrated partial responses in some patients, highlighting the potential of immunotherapy to improve survival outcomes.
- Radioembolization and Chemoembolization: Transarterial chemoembolization (TACE) and yttrium-90 radioembolization are used as palliative therapeutics to control tumor growth and bleeding. These interventions can be particularly beneficial for patients with unresectable tumors, providing symptom relief and potentially extending survival.
Table 1. Summary of therapy modalities and clinical outcomes of primary hepatic angiosarcoma based on previous retrospective and prospective studies. (Ramakrishnan N., et al., 2023)
| References |
Time period |
No. patients (n) |
Therapeutics modalities |
Clinical outcomes |
| Dannaher et al |
1974–1976 |
4 |
Adriamycin/cytoxan/methotrexate (n=3); adriamycin (n=1) |
Median OS: 14 mo |
| Kim et al |
1985–2007 |
5 |
Docetaxel/cisplatin/flouracil (n=2); docetaxel/cisplatin/flouracil, ifosfamide/doxorubicin through hepatic artery, ifosfamide/doxorubicin (n=1); ifosfamide/doxorubicin, paclitaxel, bevacizumab (n=1); conservative therapy (n=1) |
Median OS: 2.8 mo |
| Duan et al |
1999–2005 |
6 |
Curative hepatic resection (n=4); curative hepatic resection +carboplatin/pirarubicin (n= 1); palliative hepatic resection (n= 1) |
Curative resection: 1 y OS: 100%; 3 y OS: 80%; 5 y OS: 40% |
| Wilson et al |
1999–2017 |
44 |
Surgical resection (n=10); TACE, radioembolization, or external beam radiation (n=6); systemic therapy (taxol-based regimen, mitomycin/adriamycin/cisplatin, gemcitabine-based regimen, pazopanib, bevacizumab) (n=18); conservative therapy (n=13) |
1 y OS: 30%; 3 y OS: 8.1%; 5 y OS: 5.6% |
| Park et al |
2002–2007 |
6 |
TACE (n=4); TAE (n=2) |
Median OS: 3.5 mo |
| Hur et al |
2002–2012 |
8 |
Hepatic resection (n=1); TACE (n=1); systemic therapy (doxorubicin/ifosfamide +/- docetaxel or paclitaxel) (n=4); conservative therapy (n=2) |
Median OS: 7 mo |
| Tripke et al |
2002–2017 |
9 |
Surgical resection (n=4); neoadjuvant paclitaxel+surgical resection (n=1); surgical resection+adjuvant doxorubicin/ifosfamide (n=1); surgical resection+paclitaxel (n=1); surgical resection+TACE+ifosfamide/doxorubicin (n=1) |
Median OS: 7 mo |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen is committed to advancing the diagnostics and therapeutics of Primary Hepatic Angiosarcoma (PHA). We offer a comprehensive suite of services that cover the entire spectrum of PHA research and development. From early-stage biomarker discovery to preclinical drug testing, our team of expert scientists utilizes cutting-edge technologies and innovative methodologies to tackle the unique challenges posed by this rare and aggressive malignancy.
Disease Models
- Murine Hepatic Angiosarcoma Cell Lines
- Hepatic Angiosarcoma Organoids
- Diethylnitrosamine (DENA)-Induced Pig Models
- Notch1-Deficient Mouse Models
- Cell Line-Derived Xenograft Models
Protheragen's preclinical research services encompass a wide range of activities, including in vitro and in vivo model development, pharmacokinetic and pharmacodynamic studies, and toxicology assessments. We utilize state-of-the-art facilities and equipment to ensure the highest standards of quality and reproducibility in our research. If you are interested in our services, please feel free to contact us.
References
- Jiang, Lei, et al. "Clinical characteristics and surgical treatments of primary hepatic angiosarcoma." BMC gastroenterology 21.1 (2021): 156.
- Ramakrishnan, Neeraj, et al. "Management strategies and outcomes in primary liver angiosarcoma." American journal of clinical oncology 46.10 (2023): 439-444.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
